Stay updated on Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.

Latest updates to the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check14 days agoChange DetectedThe page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with a revision update to v2.16.1.SummaryDifference1%
- Check21 days agoChange DetectedThe page has been updated to reflect a new version (v2.16.0) and includes new dates for updates, specifically May 20 and May 22, 2025, while removing previous dates from February 2025.SummaryDifference0.7%
- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check57 days agoChange DetectedThe webpage has been updated to include new information about the study on metastatic melanoma, specifically detailing the drugs and therapies involved, as well as the collaborators and study version. Notably, the previous details regarding the purpose and endpoints of the pilot study have been removed.SummaryDifference39%
- Check64 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date of February 10, 2025, has been added. However, the deletion of the date March 25, 2025, does not significantly impact core content.SummaryDifference0.3%
Stay in the know with updates to Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.